Swedish Orphan Biovitrum publ AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Swedish Orphan Biovitrum publ AB Maintains FY 2013 Revenue Guidance
Swedish Orphan Biovitrum publ AB (SOBI) announced that the Company's outlook for the fiscal year 2013 remains unchanged with the total revenues for the full fiscal year 2013 expected to be in the range of SEK 2,000 million to SEK 2,200 million. According to I/B/E/S Estimates analysts on average are expecting SOBI to report revenue of SEK 2,122.53 million for the fiscal year 2013.
Latest Developments for Swedish Orphan Biovitrum publ AB
- Swedish Orphan Biovitrum publ AB maintains FY 2014 financial guidance
- FDA approves Swedish Orphan Biovitrum and Biogen Idec Eloctate
- Swedish Orphan Biovitrum elects Ernst & Young as auditor
- Swedish Orphan Biovitrum and Biogen Idec announce positive efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate for haemophilia A
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this